Marijke Dieltjens1, Marc J Braem2, Anneclaire V M T Vroegop3, Kristien Wouters4, Johan A Verbraecken5, Wilfried A De Backer5, Paul H Van de Heyning6, Olivier M Vanderveken6. 1. Department of Special Care Dentistry, Antwerp University Hospital, Edegem; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. Electronic address: Marijke.Dieltjens@uza.be. 2. Department of Special Care Dentistry, Antwerp University Hospital, Edegem; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. 3. Department of Otolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. 4. Department of Scientific Coordination and Biostatistics, Antwerp University Hospital, Edegem. 5. Department of Pneumology, Antwerp University Hospital, Edegem; Multidisciplinary Sleep Disorders Center, Antwerp University Hospital, Edegem; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. 6. Department of Otolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem; Multidisciplinary Sleep Disorders Center, Antwerp University Hospital, Edegem; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Abstract
BACKGROUND: Assessment of the overall therapeutic effectiveness of oral appliance therapy can only be realized through objectively measured compliance. The aims of this study were to assess objectively measured compliance during oral appliance therapy at 1-year follow-up and to compare these data with self-reported use. METHODS: Fifty-one eligible patients were enrolled in this 1-year prospective clinical study (men, 61%; mean age, 49 ± 10 years; apnea-hypopnea index, 18.0 ± 11.9 events/h sleep; BMI, 26.6 ± 4.1 kg/m²). Objective compliance during oral appliance therapy at 1-year follow-up was assessed with a microsensor thermometer. Subjective compliance was assessed by self-report. Patients with a mean objectively measured use of ≥ 4 h/night on 70% of nights monitored were considered regular users. The mean disease alleviation was calculated as a measure of overall therapeutic effectiveness. RESULTS: High agreement between objective and subjective compliance data at 1-year follow-up was reported (intraclass correlation coefficient, 0.8; 95% CI, 0.5-0.9), showing a mean subjective overestimation of 30 min (95% CI, -3.1 to 1.9; P = .02). The discontinuation rate at 1-year follow-up was 9.8%. The objective mean use rate was 6.4 ± 1.7 h/night at 1-year follow-up in continuing users, with a regular use rate of 83%. The mean disease alleviation was 54.9%. CONCLUSIONS: This study is the first to our knowledge to report the 1-year results of objectively measured compliance during oral appliance therapy. In addition, a high agreement between objective and subjective compliance data were reported, with a mean subjective overestimation of 30 min. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01284881; URL: www.clinicaltrials.gov.
BACKGROUND: Assessment of the overall therapeutic effectiveness of oral appliance therapy can only be realized through objectively measured compliance. The aims of this study were to assess objectively measured compliance during oral appliance therapy at 1-year follow-up and to compare these data with self-reported use. METHODS: Fifty-one eligible patients were enrolled in this 1-year prospective clinical study (men, 61%; mean age, 49 ± 10 years; apnea-hypopnea index, 18.0 ± 11.9 events/h sleep; BMI, 26.6 ± 4.1 kg/m²). Objective compliance during oral appliance therapy at 1-year follow-up was assessed with a microsensor thermometer. Subjective compliance was assessed by self-report. Patients with a mean objectively measured use of ≥ 4 h/night on 70% of nights monitored were considered regular users. The mean disease alleviation was calculated as a measure of overall therapeutic effectiveness. RESULTS: High agreement between objective and subjective compliance data at 1-year follow-up was reported (intraclass correlation coefficient, 0.8; 95% CI, 0.5-0.9), showing a mean subjective overestimation of 30 min (95% CI, -3.1 to 1.9; P = .02). The discontinuation rate at 1-year follow-up was 9.8%. The objective mean use rate was 6.4 ± 1.7 h/night at 1-year follow-up in continuing users, with a regular use rate of 83%. The mean disease alleviation was 54.9%. CONCLUSIONS: This study is the first to our knowledge to report the 1-year results of objectively measured compliance during oral appliance therapy. In addition, a high agreement between objective and subjective compliance data were reported, with a mean subjective overestimation of 30 min. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01284881; URL: www.clinicaltrials.gov.
Authors: Benjamin K Tong; Carolin Tran; Andrea Ricciardiello; Alan Chiang; Michelle Donegan; Nick Murray; Irene Szollosi; Jason Amatoury; Jayne C Carberry; Danny J Eckert Journal: J Clin Sleep Med Date: 2020-04-15 Impact factor: 4.062
Authors: Jolien Beyers; O M Vanderveken; C Kastoer; A Boudewyns; I De Volder; A Van Gastel; J A Verbraecken; W A De Backer; M J Braem; P H Van de Heyning; M Dieltjens Journal: Sleep Breath Date: 2019-02-18 Impact factor: 2.816
Authors: Chloé Kastoer; Marijke Dieltjens; Eline Oorts; Evert Hamans; Marc J Braem; Paul H Van de Heyning; Olivier M Vanderveken Journal: J Clin Sleep Med Date: 2016-10-15 Impact factor: 4.062